New drug combo aims to boost breast cancer remission before surgery
NCT ID NCT07317778
First seen Jan 09, 2026 · Last updated May 10, 2026 · Updated 31 times
Summary
This study tests whether adding the immunotherapy drug adebrelimab and/or the targeted drug SHR-A1811 to standard chemotherapy can help more people with HR-positive, HER2-low early breast cancer achieve a complete response (no cancer found at surgery). About 249 participants will receive either standard chemo alone, chemo plus adebrelimab, or a sequence of SHR-A1811 plus adebrelimab followed by chemo plus adebrelimab. The goal is to see if the new combinations are more effective and safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021, China
Conditions
Explore the condition pages connected to this study.